Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs

Aplaviroc (AVC), an experimental CCR5 inhibitor, potently blocks in vitro the infection of R5-tropic human immunodeficiency virus type 1 (R5-HIV-1) at subnanomolar 50% inhibitory concentrations. Although maraviroc is presently clinically available, further studies are required to determine the role...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nakata, Hirotomo, Steinberg, Seth M., Koh, Yasuhiro, Maeda, Kenji, Takaoka, Yoshikazu, Tamamura, Hirokazu, Fujii, Nobutaka, Mitsuya, Hiroaki
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2008
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2415794/
https://ncbi.nlm.nih.gov/pubmed/18378711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01299-07
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados